Gastric Cancer O drug refers to Navulizumab Injection, a PD-1 class immunosuppressant for the treatment of gastric cancer. Navulizumab Injection is an immune checkpoint inhibitor and can be used in combination with chemotherapy (a chemotherapy regimen containing fluorouracil and platinum agents) for the first-line treatment of advanced or recurrent adenocarcinoma of the stomach and gastroesophageal junction in patients who have previously received two or more systemic treatment regimens. Navulizumab Injection may have side effects such as rash, itching, diarrhea, headache, dizziness, hypertension, malaise, autoimmune pneumonitis, and is contraindicated in people who are allergic to it. Navulizumab injection belongs to the antitumor therapy prescription drugs, need to strictly grasp the indications and monitor the adverse reactions, so it must be applied under the guidance of the doctor, not self-application.